Fosun Pharma seeks to grow through innovation
Print Edition
FOSUN Pharmaceutical Co, a unit of Shanghai-based private conglomerate Fosun Group Co, said at the weekend it would tap innovative products and cutting edge technology to expand.
Fosun Pharma, listed in Shanghai and Hong Kong, announced a US$100 million joint venture with California-based Intuitive Surgical to research, develop, manufacture and sell innovative, robotic-assisted catheter-based medical devices.
“Innovation is at the core of our future development and growth and we’ll actively seek acquisition targets and latest technology to support our future growth,” said Fosun Pharma Chairman Chen Qiyu.
Fosun Group Chairman Guo Guangchang emphasized that “healthcare service is the most important part of Fosun Group’s blueprint and we are expediting Fosun Pharma’s investment in research and development to represent the cutting-edge technology for precision medical treatment and diagnosis.”
The joint venture, with Intuitive Surgical holding 60 percent and Fosun Pharma taking the balance, would research and develop products for early-stage diagnosis and treatment of lung cancer.
“We hope to integrate the cutting-edge R&D capabilities of Intuitive Surgical with the resources of Fosun Pharma to offer services and a healthier lifestyle for patients,” Guo said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
